3 active not recruiting, 2 recruiting, 2 terminated, 2 unknown. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 6 | Active not recruiting 3, Completed 1, Recruiting 1, Unknown 1 |
Follow Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma trials Research Report on Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2023-04-01 | 2023-01-13 | |
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Chimeric Antigen Receptor T-Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration - Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | Northwestern University | 24 | 2022-03-21 | 2024-10-16 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2020-07-27 | 2025-01-28 |
| Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy Electronic Health Record Review - Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Unknown | M.D. Anderson Cancer Center | 150 | 2020-04-02 | 2023-11-14 | |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Cyclophosphamide, Fludarabine - Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 55 | 2017-11-03 | 2024-04-10 |
| JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 30 | 2016-11-15 | 2022-08-24 |
| R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Academic and Community Cancer Research United | 30 | 2016-05-20 | 2024-07-01 |
Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · Composite Lymphoma (1) · HIV Infections (1) · Hematologic Neoplasms (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell (8) · Hematologic Diseases (2) · Infections (2) · Virus Diseases (2) · Blood-Borne Infections (1) · Communicable Diseases (1)
Cyclophosphamide (4) · fludarabine (4) · Etoposide (3) · Lenalidomide (3) · Biopsy (2) · CT-P10 (2) · Carboplatin (2) · Disulfides (2) · Ifosfamide (2) · Magnetic Resonance Spectroscopy (2) · Rituximab (2) · Specimen Handling (2) · axicabtagene ciloleucel (2) · loncastuximab tesirine (2) · ALX148 (1)
Fred Hutchinson Cancer Center (3) · M.D. Anderson Cancer Center (3) · AIDS Malignancy Consortium (1) · Academic and Community Cancer Research United (1) · City of Hope Medical Center (1) · David Bond, MD (1) · Northwestern University (1)
United States (11)
Jordan Gauthier (2) · Ariela Noy (1) · David A Bond, MD (1) · Grzegorz S Nowakowski (1) · Paolo Strati (1) · Paolo Strati, MD (1) · Raphael E Steiner (1) · Reem Karmali, MD (1) · Swetha Kambhampati (1) · Victor Chow (1)
PMID 34515338, PMID 37903325, PMID 39319495, PMID 39820359
P30CA015083 (1), P30CA015704 (1), P30CA033572 (1), P30CA060553 (1), R01CA136551 (1), UM1CA121947 (1)